Vidac Pharma present
Vidac Pharma presents high efficacy in multiple solid tumor models for its next-generation cancer drug candidate and synergy with standard-of-care treatment in liver cancer organoids
19 févr. 2024 01h30 HE | Vidac Pharma Holding PLC
London (UK), February 19, 2024, 7:30 am CET – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a...
Vidac Pharma présent
Vidac Pharma présente une efficacité élevée dans plusieurs modèles de tumeurs solides pour son candidat médicament anticancéreux de nouvelle génération, et une synergie avec le traitement standard des organoïdes du cancer du foie
19 févr. 2024 01h30 HE | Vidac Pharma Holding PLC
Londres (Royaume-Uni), 19 février 2024, 7:30 CET – Vidac Pharma Holding Plc (Hambourg et Stuttgart : T9G ; ISIN : GB00BM9XQ619 ; WKN : A3DTUQ) est une société biopharmaceutique d'oncologie de stade...
market-digits.jpg
Cancer Stem Cells Market to Accumulate a Valuation of USD 2.9 Billion by 2030, Advancing at a 11.2% CAGR | MarketDigits Richmond, Feb. 07, 2024 (GLOBE NEWSWIRE) -- According to a research report "Cancer Stem Cells Market”, by Mode of action (Targeted Cancer Stem Cell, Stem Cell-based Cancer Therapy {Autologous stem...
Global Oncologists Market
Oncologists Global Market to Reach $27.51 Billion by 2032; Asia-Pacific and North America Lead Growth
29 janv. 2024 11h35 HE | Research and Markets
Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "Oncologists Global Market Opportunities and Strategies to 2032" report has been added to ResearchAndMarkets.com's offering. The global oncologists...
22157.jpg
Anti-Cancer Monoclonal Antibodies Market to Reach $95.99 billion by 2028, with Asia Pacific Emerging as Fastest-Growing Region
22 janv. 2024 21h08 HE | Research and Markets
Dublin, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The "Anti-Cancer MAbS Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The Anti-Cancer Monoclonal Antibodies (MAbs)...
Elevar Logo for Common Use.png
Elevar Therapeutics To Present Two Posters From Phase 3 CARES-310 Study at 2024 ASCO Gastrointestinal Cancers Symposium
18 janv. 2024 08h45 HE | Elevar Therapeutics
A post hoc analysis found the efficacy of camrelizumab plus rivoceranib was superior to sorafenib regardless of baseline liver function as measured by both albumin-bilirubin grade and Child-Pugh...
Global Communities R
Global Communities Rally around Third Deadliest Cancer – Liver Cancer
01 oct. 2023 10h30 HE | Global Liver Institute
Washington, DC, Oct. 01, 2023 (GLOBE NEWSWIRE) -- Today marks the start of Liver Cancer Awareness Month, which will feature the monthlong #OctoberIs4Livers multifaceted campaign led by Global Liver...
Elevar Logo for Common Use.png
Elevar Therapeutics to Present at Cantor Fitzgerald Global Healthcare Conference
21 sept. 2023 09h00 HE | Elevar Therapeutics
FORT LEE, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating...
Elevar Logo for Common Use.png
Elevar Therapeutics Joins Benefactors Council of Blue Faery, Leading Hepatocellular Carcinoma Advocacy Group
19 sept. 2023 09h00 HE | Elevar Therapeutics
FORT LEE, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating...
Elevar Logo for Common Use.png
Elevar Therapeutics to Host August 10 Virtual KOL Event on Phase 3 Study of Rivoceranib in Combination with Camrelizumab in Unresectable Hepatocellular Carcinoma (uHCC)
03 août 2023 09h00 HE | Elevar Therapeutics
FORT LEE, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating...